eltrombopag olamine chemical name

Decrease daily dosage by 25 mg every 2 weeks to lowest dosage that maintains platelet count 50,000/mm3, In pediatric patients <12 years of age, decrease dose by 12.5 mg, Discontinue for 1 week; once platelet count is < 200,000/mm3, reinitiate eltrombopag at a daily dosage reduced by 25 mg (or 12.5 mg in pediatric patients <12 years of age). Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% saline, Solubility: 2.08 mg/mL (3.68 mM); Clear solution, Add each solvent one by one: 10% DMSO 90% (20% SBE--CD in saline), COA (256 KB) Eltrombopag 50mg + Quantity: Similar products. 'Eltrombopag olamineis an antihemorrhagic dug. 2017 Feb 28;1(7):468-476. Eltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis. Synonyms: Eltrombopag diethanolamine salt; SB-497115GR Formula: C29H36N6O6 Molecular Weight: 564.63 CAS No. Sorry, but the email address you supplied was invalid. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals and is transferred to Novartis Pharmaceuticals. Stem Cells. FIRST AID MEASURES 4.1 Description of first aid measures Eye contact Remove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. The chemical name for eltrombopag olamine is 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid - 2-aminoethanol (1:2). Eltrombopag Olamine Catalog No. Recommended Studies: Two studies . ; IC50 Value: 0.27 uM (EC50 in murine BAF3 cells) [1]; Target: thrombopoietin-receptor (c-mpl); Potential advantages of eltrombopag may include a sustained platelet response and a good tolerability profile. CAS No. Eltrombopag. Qianyan Chemical Technology (Wuhan) Co., Ltd. Request for quotation. Use eltrombopag to increase platelet counts to a level sufficient to minimize risk of bleeding. Promacta is a brand name of eltrombopag, approved by the FDA in the following formulation (s): PROMACTA (eltrombopag olamine - tablet;oral) Manufacturer: NOVARTIS Approval date: November 20, 2008 Strength (s): EQ 25MG ACID [ RLD], EQ 50MG ACID [ RLD] Manufacturer: NOVARTIS Approval date: September 8, 2009 Strength (s): EQ 75MG ACID [ RLD] Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. The chemical name for eltrombopag olamine is 3''-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro . [Content Brief], [2]. Pediatric patients 1 year of age: Maximum 75 mg once daily. the invention discloses the preparation method of eltrombopag olamine, the chemical name of the eltrombopag olamine is 3 { (2z) 2 [1 (3,4 xylyls) 3 methyl, 5 oxo, 1,5 dihydro 4h. Oral gavage; 10 mg/kg once a day; for 5 days. Eltrombopag efficiently inhibits Pneumococcal growth with MIC50 of 0.3 mg/L, but shows no activity against Gram-negative bacteria[3]. 2015 Nov;47(5):1696-702. Interacts with the transmembrane domain of the TPO receptor, initiating a cascade of intracellular signaling events leading to proliferation and differentiation of bone marrow progenitor cells within the megakaryocytic lineage and subsequently increasing the production of platelets. Increased risk of developing a hematologic malignancy, especially in patients with myelodysplastic syndrome (MDS). ;IC50 Value: 0.27 uM (EC50 in murine BAF3 cells) [1];Target: thrombopoietin-receptor (c-mpl)Potential advantages of eltrombopag may include a sustained platelet response and a good tolerability profile. UNII-4U07F515LG, Promacta, Revolade (ChemID). Do not administer more than one dose in any 24-hour period. Adjust dosage of eltrombopag based on platelet counts (see Table 8). Eltrombopag (30 M; 120 min) activates p-STAT5 in megakaryocytes[1]. Unlike recombinant TPO or romiplostim, Eltrombopag does not activate the AKT pathway in any way. . Increases in platelet counts induced by eltrombopag may result in thrombotic or thromboembolic complications. Brand Name Dosage Form Strength Company Pack Size & Price; Cytopag Tablet 50 mg ACI Limited Unit . Pharmacokinetics of caffeine unlikely to be affected, Cations, polyvalent (e.g., iron, calcium, aluminum, magnesium, selenium, zinc) found in food, mineral supplements, and antacids, Reduced plasma eltrombopag concentration in patients receiving concomitant antacid therapy containing aluminum hydroxide, magnesium carbonate, and sodium alginate, Reduced eltrombopag AUC reported in association with high-calcium, high-fat breakfast, Avoid medications and foods containing polyvalent cations, including antacids, dairy products, and mineral supplements, for at least 2 hours before or 4 hours after each dose of eltrombopag, Decreased plasma concentrations and AUC of eltrombopag by 2539% and 1824%, respectively, Hepatitis C protease inhibitors (e.g., boceprevir, telaprevir), Coadministered repeat-dose boceprevir or telaprevir did not significantly alter AUC or peak plasma concentration of eltrombopag, HIV Protease inhibitors (e.g., lopinavir/ritonavir), Coadministered repeat-dose lopinavir/ritonavir decreased plasma eltrombopag AUC by 17%, HMG-CoA reductase inhibitors (statins; e.g., atorvastatin, fluvastatin, pravastatin, rosuvastatin), Potential increased statin concentrations, Increased AUC and peak plasma concentration of rosuvastatin reported, Use caution and consider reduction of statin dosage if manifestations of excessive systemic exposure occur, Reduction in rosuvastatin dosage by 50% was recommended for patients receiving concomitant eltrombopag in clinical trials. 2021 Feb 21. Product Name: Eltrombopag Olamine: CAS Number: 496775-62-3: 1.2 Relevant identified uses of the substance or mixture and uses advised against; Identified uses: For research use only, not for human or veterinary use. preferred substance name: eltrombopag olamine; inchikey: plilluuxavkbpy-sbiavedlsa-n; synonyms and mappings. Aliquot to avoid multiple freeze/thaw cycles. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. Designated an orphan drug by FDA for treatment of ITP. Carefully read the patient information (medication guide) provided by the manufacturer before initiating therapy, and each time the prescription is refilled. Phase 2, Tel: +1-832-696-8203Fax: +1-832-641-3177 Email: [emailprotected]. Risk of worsening thrombocytopenia with possible bleeding following discontinuance of eltrombopag, especially if the drug is discontinued while the patient is receiving concomitant anticoagulant or antiplatelet drugs. When used for first-line treatment of severe aplastic anemia, monitor ALT, AST, and bilirubin every other day while hospitalized for horse antithymocyte globulin (h-ATG) therapy, then every 2 weeks during treatment. For patients with Asian ancestry or hepatic impairment, reduce initial dosage to 25 mg once daily. 2025C (excursions permitted to 1530C). Int J Oncol. Thanks, your subscription has been confirmed. Discontinuation of eltrombopag may also be required if important liver test abnormalities or excessive platelet counts occur. Type of study: Fasting Design: Single-dose, two treatment, two-period, crossover in vivo . Also used for treatment of severe aplastic anemia in patients with an insufficient response to immunosuppressive therapy. As the situation with COVID-19 continues to unfold in every community, MedChemExpress is responding to the uncertainty caused by this outbreak thoughtfully and cautiously. 2021 Feb 21. Toggle Nav ChemBK. Designated an orphan drug by FDA for use in treatment of aplastic anemia. Room temperature in continental US; may vary elsewhere. 2005 Jan;33(1):85-93. A small-molecule, nonpeptide, thrombopoietin (TPO)-receptor agonist. Monitor CBCs with differentials, including platelet counts, weekly for at least 4 weeks following discontinuance of therapy. Inhibition or induction of the metabolism of a combination of probe substrates for CYP1A2, CYP2C19, CYP2C9, or CYP3A4 not demonstrated. Routinely monitor patients for signs and symptoms of cataracts. 1. Pharmaceutical form. Eltrombopag olamine is used in certain patients with ITP who have not gotten better with other treatment. Each tablet. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. The pharmacokinetics of eltrombopag was dose dependent and linear, and eltrombopag increased platelet counts in a dose-dependent manner [4]. Erickson-Miller CL, et al. In patients with Asian ancestry or hepatic impairment, reduce initial dosage to 75 mg once daily. The Eltrombopag antitumor effect on hepatocellular carcinoma. JavaScript seems to be disabled in your browser. Whereas romiplostim is a peptide which has to be injected, eltrombopag is a small non-peptide molecule which can be given orally. Patients with low albumin levels (<3.5 g/dL) or Model for End-Stage Liver Disease (MELD) score 10 at baseline may be at greater risk. If you need to change the delivery plan for items ordered, please contact us via email [emailprotected]. Cautiously reintroduce eltrombopag while monitoring liver function weekly during the dosage adjustment phase. The molecular formula is. Retreatment may be considered if benefits are thought to outweigh the risk of hepatotoxicity. Not indicated for the treatment of thrombocytopenia associated with myelodysplastic syndrome. Initiate eltrombopag concurrently with standard immunosuppressive therapy. Initiate concurrently with standard immunosuppressive therapy. (II) is marketed in USA by . Eltrombopag olamine is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Probe substrates for CYP2C8 not evaluated. Adjust dosage based on platelet count (see Table 6); manufacturer recommends that a platelet count 50,000/mm3 be achieved and maintained as necessary to reduce risk of bleeding. Eltrombopag interacts with the transmembrane domain of the TPO receptor (also known as cMpl) leading to increased platelet production. AUC of eltrombopag is reduced in patients with mild, moderate, or severe renal impairment. Film-coated tablet. Corticosteroids remain the standard initial therapy for newly diagnosed patients with ITP, but should be used for a limited duration only because of adverse effects. DB06210. Product Name. Chronic hepatitis C: No dosage adjustment is recommended. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Gene target. Calcium-containing foods and medications may decrease the rate and extent of eltrombopag absorption; therefore, administer at least 2 hours before or 4 hours after other medications (e.g., antacids), calcium-rich foods (e.g., dairy products, certain fruits and vegetables), or supplements that contain polyvalent cations (e.g., iron, calcium, aluminum, magnesium, selenium, zinc). in vitro: Eltrombopag demonstrated a half maximal effective concentration (EC50) of 0.27 uM in murine BAF3 cells transfected with the luciferase reporter gene under direction of the STAT-activated IRF-1 promoter and human TpoR (BAF3/IRF-1/hTpoR) [1]. Eltrombopag olamine is prepared from salts of eltrombopag, which are used as intermediates. VA class: BL400 496775-61-2. Adjust dosage based on platelet count (see Table 1); manufacturer recommends that a platelet count 50,000/mm3 be achieved and maintained as necessary to reduce risk of bleeding. Phone. 496775-62-3. White, round, biconvex film-coated tablet (approximately 7.9 mm in diameter) debossed with 'GS MZ1' and '12.5' on one side. Thank you for being a loyal MedChemExpress customer, we are here to assist you as needed. Reduced initial dosages may be required in patients with mild to severe hepatic impairment (Child-Pugh class A, B, or C). Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well. Eltrombopag Olamine can be used for the research of cardiovascular. Significantly induced G0/G1 phase arrest. All of the co-solvents are available by MCE. Eltrombopag 50 milligrams of pure chemical substance for laboratory research. Juan Zhu, et al. Promoted BAF3/hTpoR cells proliferation after incubated for 2 days with an EC, Dose-dependently stimulated the differentiation from bone marrow CD34, 0, 0.003, 0.01, 0.03, 0.1, 0.3, 1 and 3 M. Synonyms. [4]. Patients with chronic hepatitis C and hepatic impairment have increased plasma concentrations and prolonged half-life of eltrombopag. Promacta. (Synonyms: Eltrombopag diethanolamine salt; SB-497115GR). CAS number: 496775-62-3. Chemical name: 3-{(2Z)-2-[1-(3, 4-dimethylphenyl)-3-methyl-5-oxo-1, 5-dihydro-4H-pyrazol-4-ylidene] hydrazino}-2-hydroxy-3-biphenylcarboxylic acid-2-aminoethanol (1:2) Amines Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. . Available data in pregnant women insufficient to assess drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Small-molecule thrombopoietin receptor agonist (TPO-RA). This page contains information about (Z)-3`-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)-1-nitrosohydrazinyl)-2`-hydroxy-[1,1`-biphenyl . Your need for high quality reagent doesn't stop during difficult times, and neither do we. The chemical Eltrombopag olamine has a designated molecular formula of C29H36N6O6 and a molecular weight of 564.643 g/mol. We're professional eltrombopag olamine cas 496775-62-3 manufacturers and suppliers in China, specialized in providing high quality API, intermediates and fine chemicals. Articles of Eltrombopag olamine are included as well. The chemical Eltrombopag olamine has a designated molecular formula of C29H36N6O6 and a molecular weight of 564.643 g/mol. Chemistry. Brand name: Promacta RP-HPLC (311 KB) Eltrombopag olamine. Advise women to inform their clinicians if they are or plan to become pregnant or plan to breast-feed. Use concomitantly with caution and consider dosage reduction of the substrate drug if appropriate. Jigs chemical is global Manufacturer, supplier of Eltrombopag olamine,496775-62-3, industrial chemicals, solvents, exporters, Sourcing, Distributor, bulk, MSDS, specification & COA, documentation, as per requirements of RND/ Development or commercial quantities with best price Product Name Eltrombopag olamine Buy In Stock CAS 496775-62-3 Tel Moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C): Eltrombopag AUC is approximately 2-fold higher; half-life prolonged 2-fold. Antibiotics (Basel). Pharmacokinetics of eltrombopag are dose proportional over the dosage range of 50 to 150 mg daily. Metabolites associated with glucuronidation and oxidation detected. In patients with ITP and hepatic impairment (Child-Pugh class A, B, or C), dosage should be increased no sooner than 3 weeks after initiation of eltrombopag or after any subsequent dosage increase. Indicated for use only in patients in whom the degree of thrombocytopenia prevents initiation or continuation of interferon-based therapy. Toxicity: There were no apparent differences in the incidence or severity of adverse events in subjects receiving active or placebo study medication [4]. Monitor hepatic function and discontinue as recommended. 2009 Feb;27(2):424-30. This website collects cookies to deliver a better user experience. Substrates of OATP1B1 or BCRP: Potential pharmacokinetic interaction (increased concentrations) of concomitantly administered OATP1B1 substrates (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or BCRP substrates (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). For patients with Asian ancestry (such as Chinese, Japanese, Taiwanese, Korean, or Thai) or who have mild to severe hepatic impairment (Child-Pugh class A, B, or C), initiate at a reduced dosage of 25 mg once daily. Monitor liver function tests (e.g., ALT, AST, bilirubin) every 2 weeks during the dose adjustment phase and then monthly during establishment of a stable dosage; if any abnormalities are found, monitor serum liver function tests weekly until resolution or stabilization. Use a new oral dosing syringe to prepare each dose of the oral suspension. ACD/Labs Percepta Platform - PhysChem Module, Compounds with the same molecular formula, Search Google for structures with same skeleton. Synonyms may include: SB 497115GR, UNII-4U07F515LG, Promacta, Revolade (ChemID). It is a thrombopoietin receptor agonist. We serve Chemical Name:Eltrombopag olamine CAS:496775-62-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. CAS Common Chemistry. . Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine. Polyvalent cations in food or supplements will be chelated by eltrombopag; therefore, they should be separated by 4 hours before or 2 hours after taking eltrombopag. Adjust dosage in 25-mg increments every 2 weeks as necessary to achieve the target platelet count required to initiate antiviral therapy (see Table 7). Discontinue therapy if the platelet count has not reached a level sufficient to avoid clinically relevant bleeding after 4 weeks of treatment at the maximum recommended dosage. . . Juan Zhu, et al. 2021 Nov 9;10(11):1372. More than 140,000 products, 270,000 supply sources and 4,400 company addresses. Catalog number: A3387-100 . . Increase daily dosage by 25 mg to a maximum of 100 mg daily, Discontinue eltrombopag and increase frequency of platelet monitoring to twice weekly, Once platelet count is <150,000/mm3, reinitiate therapy at a daily dosage reduced by 25 mg, For patients taking a dosage of 25 mg once daily, reinitiate therapy at a dosage of 12.5 mg daily. Blood Adv. Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. ;In vivo: Twelve weeks of antiviral therapy, with concurrent receipt of eltrombopag or placebo, were completed by 36%, 53%, and 65% of patients receiving 30 mg, 50 mg, and 75 mg of eltrombopag, respectively, and by 6% of patients in. Your information is safe with us. Search for free and find new suppliers for chemical products, pharmaceuticals and APIs. Filter by: Clear. TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY. Perform a baseline ocular examination prior to eltrombopag therapy; monitor periodically for signs and symptoms of cataracts during therapy. Description: IC50 Value: 0.27 uM (EC50 in murine BAF3 cells) [1] Eltrombopag is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis. Eltrombopag 50mg . Extensively metabolized, predominantly through pathways including cleavage, oxidation (CYP1A2 and CYP2C8), and conjugation with glucuronic acid (via UGT1A1 and UGT1A3), glutathione, or cysteine. CAS Name Eltrombopag olamine Molecular Formula C 25 H 22 N 4 O 4.2C 2 H 7 NO Discover more in SciFinder n. Cite this Page Eltrombopag olamine. A3387 C-mpl agonist Skip to the end of the images gallery Skip to the beginning of the images gallery Tel: +1-832-696-8203 Email: sales@apexbt.com Worldwide Distributors Bulk Inquiry Add to Cart Check Out Background Chemical Properties Quality Control Background Revolade 12.5 mg film-coated tablets. Distributes into blood cells; concentrations in blood cells about 5079% of plasma concentrations.

Do Vacuum Bags Prevent Mould, How To Create A Portfolio On Weebly, How To Sell On Paypal Without Getting Scammed, Expo Hotel Barcelona Email, Zhoug Sauce Where To Buy,